|
DGAP-News: Biotest AG
/ Key word(s): Miscellaneous
11.12.2019 / 07:00
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Biotest AG opens fourth plasma collection centre in Czech Republic
- 22 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 11 December 2019. Biotest received an operating permit for its fourth plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre is located in Jihlava in completely redesigned premises. With the additional centre, Biotest can increase its self-sufficiency ratio and is prepared for future growth.
Cara Plasma s.r.o. is a 100% subsidiary of Biotest AG and operates four plasma collection centres in the Czech Republic. "We are very happy to be able to open another collecting station in the Czech Republic this year. With the new centre, we are creating 25 highly qualified jobs in the medical sector. Each additional station is an important milestone for us to supply our plasma production facility with the opportunity to support patients worldwide in the fight against diseases", stated Martin Reinecke, Senior Vice President of Global Plasma Alliances and Protein Supply of Biotest AG.
The collected plasma is processed only by Biotest AG at Dreieich, Germany. Regular audits in Czech Republic ensure that the strict legal and internal quality requirements are met.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de
PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
11.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
